(ANIK) Anika Therapeutics - Ratings and Ratios
Hyaluronic Acid, Joint Injections, Surgical Sealants
ANIK EPS (Earnings per Share)
ANIK Revenue
Description: ANIK Anika Therapeutics August 18, 2025
Anika Therapeutics Inc (NASDAQ:ANIK) is a biotechnology company listed on the NASDAQ stock exchange, operating within the biotechnology sub-industry. The companys stock performance and financial health are critical indicators for investors and analysts.
Given the negative Return on Equity (RoE) of -38.50, it is evident that Anika Therapeutics is currently not generating profits from shareholders equity, suggesting potential operational or strategic challenges. The forward Price-to-Earnings (P/E) ratio of 833.33 indicates high growth expectations or potentially overvalued stock, considering the current lack of earnings. The Market Capitalization stands at $125.73 million, categorizing it as a small-cap company with potential for growth or volatility.
Key Performance Indicators (KPIs) to monitor for Anika Therapeutics include revenue growth, R&D expenditure as a percentage of revenue, and cash burn rate. The companys ability to bring new products to market, navigate regulatory environments, and manage its cash resources effectively will be crucial. Economic drivers such as the demand for biotechnology products, patent expirations, and competition within the industry will significantly impact Anikas financial performance.
From a trading perspective, the stocks beta of 0.637 suggests it is less volatile than the overall market, potentially appealing to risk-averse investors. However, the current price of $8.83 being closer to the 52-week low of $8.10 than the high of $26.75 indicates a significant decline in stock value over the past year, which could be due to various factors including market sentiment, product performance, or broader industry challenges.
To assess the viability of Anika Therapeutics as an investment, it is essential to analyze its product pipeline, partnerships, and financial management strategies closely. The quarterly tax provision data may offer insights into the companys tax strategies and potential impacts on profitability. Understanding these elements can provide a clearer picture of the companys future prospects and potential for return on investment.
ANIK Stock Overview
| Market Cap in USD | 141m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 1993-04-29 |
ANIK Stock Ratings
| Growth Rating | -88.1% |
| Fundamental | 31.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -50.8% |
| Analyst Rating | 4.67 of 5 |
ANIK Dividends
Currently no dividends paidANIK Growth Ratios
| Growth Correlation 3m | 69.8% |
| Growth Correlation 12m | -90.9% |
| Growth Correlation 5y | -82.7% |
| CAGR 5y | -32.89% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.44 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.96 |
| Sharpe Ratio 12m | -0.08 |
| Alpha | -56.29 |
| Beta | 0.619 |
| Volatility | 37.61% |
| Current Volume | 153.6k |
| Average Volume 20d | 89.7k |
| Stop Loss | 9.2 (-5.6%) |
| Signal | -0.04 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-60.6m TTM) > 0 and > 6% of Revenue (6% = 7.42m TTM) |
| FCFTA -0.00 (>2.0%) and ΔFCFTA -0.72pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 67.27% (prev 77.23%; Δ -9.96pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.03 (>3.0%) and CFO 6.28m > Net Income -60.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 6.18 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (14.3m) change vs 12m ago -3.42% (target <= -2.0% for YES) |
| Gross Margin 38.96% (prev 61.88%; Δ -22.92pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 54.96% (prev 63.54%; Δ -8.58pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -34.31 (EBITDA TTM -29.1m / Interest Expense TTM 1.04m) >= 6 (WARN >= 3) |
Altman Z'' 4.46
| (A) 0.44 = (Total Current Assets 99.3m - Total Current Liabilities 16.1m) / Total Assets 187.7m |
| (B) 0.33 = Retained Earnings (Balance) 62.8m / Total Assets 187.7m |
| (C) -0.16 = EBIT TTM -35.8m / Avg Total Assets 225.2m |
| (D) 1.45 = Book Value of Equity 58.2m / Total Liabilities 40.0m |
| Total Rating: 4.46 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 31.49
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -0.47% = -0.24 |
| 3. FCF Margin -0.43% = -0.16 |
| 4. Debt/Equity 0.17 = 2.49 |
| 5. Debt/Ebitda 0.97 = 1.81 |
| 6. ROIC - WACC (= -34.15)% = -12.50 |
| 7. RoE -38.50% = -2.50 |
| 8. Rev. Trend -71.07% = -5.33 |
| 9. EPS Trend 18.38% = 0.92 |
What is the price of ANIK shares?
Over the past week, the price has changed by -0.31%, over one month by +5.29%, over three months by +18.18% and over the past year by -43.54%.
Is Anika Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ANIK is around 6.95 USD . This means that ANIK is currently overvalued and has a potential downside of -28.72%.
Is ANIK a buy, sell or hold?
- Strong Buy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ANIK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 15.5 | 59% |
| Analysts Target Price | 15.5 | 59% |
| ValueRay Target Price | 7.7 | -21.2% |
ANIK Fundamental Data Overview November 01, 2025
P/E Forward = 50.7614
P/S = 1.2335
P/B = 0.8904
P/EG = 5.0667
Beta = 0.619
Revenue TTM = 123.7m USD
EBIT TTM = -35.8m USD
EBITDA TTM = -29.1m USD
Long Term Debt = 25.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.63m USD (from shortTermDebt, last quarter)
Debt = 25.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -28.2m USD (from netDebt column, last quarter)
Enterprise Value = 113.1m USD (141.3m + Debt 25.0m - CCE 53.2m)
Interest Coverage Ratio = -34.31 (Ebit TTM -35.8m / Interest Expense TTM 1.04m)
FCF Yield = -0.47% (FCF TTM -535.0k / Enterprise Value 113.1m)
FCF Margin = -0.43% (FCF TTM -535.0k / Revenue TTM 123.7m)
Net Margin = -48.99% (Net Income TTM -60.6m / Revenue TTM 123.7m)
Gross Margin = 38.96% ((Revenue TTM 123.7m - Cost of Revenue TTM 75.5m) / Revenue TTM)
Gross Margin QoQ = 50.90% (prev 56.10%)
Tobins Q-Ratio = 0.60 (Enterprise Value 113.1m / Total Assets 187.7m)
Interest Expense / Debt = 2.52% (Interest Expense 629.0k / Debt 25.0m)
Taxrate = -17.17% (negative due to tax credits) (681.0k / -3.97m)
NOPAT = -42.0m (EBIT -35.8m * (1 - -17.17%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 6.18 (Total Current Assets 99.3m / Total Current Liabilities 16.1m)
Debt / Equity = 0.17 (Debt 25.0m / totalStockholderEquity, last quarter 147.7m)
Debt / EBITDA = 0.97 (negative EBITDA) (Net Debt -28.2m / EBITDA -29.1m)
Debt / FCF = 52.67 (negative FCF - burning cash) (Net Debt -28.2m / FCF TTM -535.0k)
Total Stockholder Equity = 157.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -32.30% (Net Income -60.6m / Total Assets 187.7m)
RoE = -38.50% (Net Income TTM -60.6m / Total Stockholder Equity 157.5m)
RoCE = -19.63% (EBIT -35.8m / Capital Employed (Equity 157.5m + L.T.Debt 25.0m))
RoIC = -26.65% (negative operating profit) (NOPAT -42.0m / Invested Capital 157.5m)
WACC = 7.50% (E(141.3m)/V(166.3m) * Re(8.30%) + D(25.0m)/V(166.3m) * Rd(2.52%) * (1-Tc(-0.17)))
Discount Rate = 8.30% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.08%
Fair Price DCF = unknown (Cash Flow -535.0k)
EPS Correlation: 18.38 | EPS CAGR: 0.17% | SUE: -0.04 | # QB: 0
Revenue Correlation: -71.07 | Revenue CAGR: -12.13% | SUE: 0.11 | # QB: 0
Additional Sources for ANIK Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle